We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Treatment with Mesenchymal Stem Cells Effective in Animal Autoimmune Disease Models

By LabMedica International staff writers
Posted on 14 May 2012
A paper demonstrated how autoimmune disorders could be controlled by infusions of mesenchymal stem cells.

Mesenchymal stem cells (MSC) are adult stem cells traditionally found in the bone marrow. More...
However, mesenchymal stem cells can also be isolated from other tissues including cord blood, peripheral blood, fallopian tube, and fetal liver and lung. MSCs are multipotent stem cells, which differentiate to form adipocytes, cartilage, bone, tendons, muscle, and skin.

Investigators at the University of Southern California (Los Angeles, USA) worked with animal models of various autoimmune disorders. In the current study they showed that in mice systemic infusion of bone marrow MSCs induced transient T-cell apoptosis via the FAS ligand (FASL)-dependent FAS pathway and could ameliorate autoimmune disease symptoms in fibrillin-1 mutated systemic sclerosis (SS) and dextran-sulfate-sodium-induced experimental colitis.

Fas ligand (FasL or CD95L) is a type-II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Binding for FASL to the FAS receptor induces apoptosis. Fas ligand/receptor interactions play an important role in the regulation of the immune system and the progression of cancer. Bone marrow MSCs that lacked the gene for production of FASL did not induce T cell apoptosis in recipients, and could not ameliorate SS and colitis.

Mechanistic analysis that was published in the April 26, 2012, online edition of the journal Cell Stem Cell revealed that FAS-regulated monocyte chemotactic protein 1 (MCP-1) secretion by bone marrow MSCs recruited T-cells for FASL-mediated apoptosis. The apoptotic T cells subsequently triggered macrophages to produce high levels of transforming growth factor beta (TGF-beta), which in turn led to the upregulation of CD4+CD25+Foxp3+ regulatory T-cells and, ultimately, immune tolerance.

“The identification of the cellular workings responsible for the stem cell treatments' success may eventually help doctors find optimal cell-based treatment for some immune diseases,” said senior author Dr. Songtao Shi, professor of molecular biology at the University of Southern California.

Related Links:

University of Southern California




New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Steam Sterilizer
Hi Vac II Line
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.